Dr Reddy's Laboratories reported a 69% year-on-year decline in Q1 FY27 net profit to ₹4,435 crore, impacted by lower global generics revenue, weak North America sales and semaglutide supply disruptions. The company's revenue fell 5.5%, while EBITDA also declined sharply. Semaglutide production issues added further pressure on quarterly performance.